• Home
  • About
  • Team
  • JOTROL™​
    • JOTROL™​ Pre-Clinical Studies
  • Pipeline
    • Friedreich's Ataxia (JOT101) >
      • JOT101 Project Advisors
    • Alzheimer's Disease (JOT108)
  • Partners
  • News
  • Contact
    • Investors
  • Resveratrol science
  • Policies
Jupiter Orphan Therapeutics
  • Home
  • About
  • Team
  • JOTROL™​
    • JOTROL™​ Pre-Clinical Studies
  • Pipeline
    • Friedreich's Ataxia (JOT101) >
      • JOT101 Project Advisors
    • Alzheimer's Disease (JOT108)
  • Partners
  • News
  • Contact
    • Investors
  • Resveratrol science
  • Policies
Picture
JOT is developing JOTROL™​ for Alzheimer's Disease in parallel with Mucopolysaccharidosis Type-1 and Friedreich's Ataxia to utilize the possible fast approval and income stream of a rare disease to fund AD development. Additional rare diseases might be developed later.
Upcoming results from the Phase I Pharmacokinetics Study will be cross-referenced, works as an FDA "master file", for all future 
JOTROL™​ indications enabling direct to Phase II trials.
​
Proudly powered by Weebly
  • Home
  • About
  • Team
  • JOTROL™​
    • JOTROL™​ Pre-Clinical Studies
  • Pipeline
    • Friedreich's Ataxia (JOT101) >
      • JOT101 Project Advisors
    • Alzheimer's Disease (JOT108)
  • Partners
  • News
  • Contact
    • Investors
  • Resveratrol science
  • Policies